Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3701_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
34 Мб
Скачать
Novel Pathogenesis and Treatments for Cardiovascular Disease
61
https://t.me/medicina_free
[73] Rey M, Weber E, Hess PD.
Simultaneous pulmonary and systemic blood pressure and ECG interval measurement in conscious, freely moving rats. Journal of the American Association for Laboratory Animal Science. 2012;(2):231-238
[74] Jiang M, Murias JM, Chrones T,
Sims SM, Lui E, Noble EG. American ginseng acutely regulates contractile function of rat heart. Frontiers in Pharmacology. 2014;:43
[75] Imoto K, Hirakawa M, Okada M,
Yamawaki H. Canstatin modulates L-type calcium channel activity in rat ventricular cardiomyocytes. Biochemical and Biophysical Research Communications. 2018;(4):954-959
[76] Kruger C, Landerer V, Zugck C,
Ehmke H, Kubler W, Haass M. The bradycardic agent zatebradine enhances baroreflex sensitivity and heart rate variability in rats early after myocardial infarction. Cardiovascular Research. 2000;(4):900-912
[77] Dai GF, Wang ZJY. Octreotide
protects doxorubicin-induced cardiac toxicity via regulating oxidative stress. European Review for Medical and Pharmacological Sciences. 2018;(18):6139-6148
[80] Trindade DC, Trindade RC,
Marassi MP, Martins OPPR, Costa­E-Sousa RH, Mattos EC, etal. Role of renin-angiotensin system in development of heart failure induced by myocardial infarction in rats. Anais da Academia Brasileira de Ciências. 2007;(2):251-259
[81] Yenisehirli A, Naseri E. Omeprazole,
lansoprazole and pantoprazole had no effect on blood pressure and electrocardiogram of anesthetized rat. Pharmacological Research. 2008;(1):65-71
[82] Parasuraman S, Raveendran R,
Selvaraj RJ. Effects of cleistanthins a and B on blood pressure and electrocardiogram in Wistar rats. Zeitschrift für Naturforschung C. 2011;(11-12):581-587
[83] Kannan M, Quine SD. Ellagic acid
ameliorates isoproterenol induced oxidative stress: Evidence from electrocardiological, biochemical and histological study. European Journal of Pharmacology. 2011;(1):45-52
[84] Mutiso SK, Rono DK, Bukachi F.
Relationship between anthropometric measures and early electrocardiographic changes in obese rats. BMC Research Notes. 2014;:931
[78] Mao PR, Jamali F. Methoxyflurane
anesthesia augments the chronotropic and dromotropic effects of verapamil. Journal of Pharmacy & Pharmaceutical Sciences. 1999;(1):30-35
[79] Regan CP, Cresswell HK,
Zhang R, Lynch JJ. Novel method to assess cardiac electrophysiology in the rat: Characterization of standard ion channel blockers. Journal of Cardiovascular Pharmacology. 2005;(1):68-75

[85] Selcuk EB, Sungu M, Parlakpinar H,
Ermis N, Taslidere E, Vard N, etal. Evaluation of the cardiovascular effects of varenicline in rats. Drug Design, Development and Therapy. 2015;:5705-5717
[86] Binu P, Priya N, Abhilash S,
Vineetha RC, Nair RH. Studies on curative efficacy of monoterpene eugenol on anti- leukemic drug arsenic trioxide induced cardiotoxicity. Biomedicine & Pharmacotherapy. 2017;:559-566
Rat Electrocardiography and General Anesthesia DOI: http://dx.doi.org/10.5772/.104928
[87]
62
https://t.me/medicina_free
Bora S, Erdogan MA, Yigitturk G, Erbas O, Parlak I. The effects of lipid emulsion, magnesium sulphate and metoprolol in amitriptyline­induced cardiovascular toxicity in rats. Cardiovascular Toxicology. 2018;(6):547-556
[88]
Pişkin Ö, Ayoğlu H. Effects of remifentanil pretreatment on bupivacaine cardiotoxicity in rats. Cardiovascular Toxicology. 2018;(1):56-62
[89]
Arini PD, Liberczuk S, Mendieta JG, Santa María M, Bertrán GC. Electrocardiogram delineation in a Wistar rat experimental model. Computational and Mathematical Methods in Medicine. 2018;(3):1-10
[90]
Ramezani-Aliakbari F, Badavi M, Dianat M, Mard SA, Ahangarpour A. The effects of trimetazidine on QT-interval prolongation and cardiac hypertrophy in diabetic rats. Arquivos Brasileiros de Cardiologia. 2019;(2):173-178
[91]
Sohrabi F, Dianat M, Badavi M, Radan M, Mard SA. Does gallic acid improve cardiac function by attenuation of oxidative stress and inflammation in an elastase-induced lung injury? Iranian Journal of Basic Medical Sciences. 2020;:1130-1138
[92]
Boarescu PM, Boarescu I, Bulboacă AE, Bocsan IC, Pop RM, Gheban D, etal. Multi-organ protective effects of curcumin nanoparticles on drug-induced acute myocardial infarction in rats with type 1 diabetes mellitus. Applied Sciences. 2021;:5497
[93]
Miranda A, Costa-e-Sousa RH, Werneck-de-Castro JP, Mattos EC, Olivares EL, Ribeiro VP, etal. Time course of echocardiographic and electrocardiographic parameters in myocardial infarct in rats. Anais
da Academia Brasileira de Ciências. 2007;:639-648
[94] Ketabchi F, Sepehrinezhad A,
Dehghanian A. The relationship between liver dysfunction, electrocardiographic abnormalities and metabolism in rat. Journal of Clinical and Experimental Cardiology. 2018;(10):1000610
[95] Kumar P, Verma S, Singh S,
Tiwari S, Khan MY. Effect of Aloe vera (Aloe barbadensis) gel extract on repolarization state of myocardium in albino rat. African Journal of Pharmacy and Pharmacology. 2010;(12):885-889
[96] Barrasa JLM, Rodriguez NS,
Rodriguez-Perez JC, Hidalgo AC, Garcia AT, Camarillo JAI, etal. Electrocardiographic changes in rats undergoing thoracic surgery under combined parenteral anesthesia. Lab Animal. 2008;(10):469-174
[97] Sedmera D, Neckar J, Benes J Jr,
Pospisilova J, Petrak J, Sedlacek K, etal. Changes in myocardial composition and conduction properties in rat heart failure model induced by chronic volume overload. Frontiers in Physiology. 2016;:367
[98] Yadav RK, Rawat JK, Gautam S,
Singh M, Kumar M, Ansari MN, Roy S, Saeedan AS, Kaithwas G. Antidiabetic activity of mefloquine via GLP-1 receptor modulation against STZ-NA-induced diabetes in albino wistar rats. 3 Biotech 2018;8(5), 1-10
[99] Normann SJ, Priest RE, Benditt EP.
Electrocardiogram in the normal rat and its alteration with experimental coronary occlusion. Circulation Research. 1961;:282-287
[100] Fraser RS, Harley C, Wiley T.
Electrocardiogram in the normal rat.

Novel Pathogenesis and Treatments for Cardiovascular Disease
63
https://t.me/medicina_free
Journal of Applied Physiology. 1967;(3):401-402
[101] Kela AK, Reddy IP, Thombre DB.
E.C.G. findings in normal rats and after administration isoproterenol. Indian Journal of Physiology and Pharmacology. 1980;(2):84-90
[102] Krandycheva VV, Kharin SN,
Shmakov DN. P-wave body surface potential distribution in rats. Journal of Electrocardiology. 2006;(1): 88-92
[103] Upaganlawar AA, Balaraman R.
Cardioprotective effects of co-administration of pomegranate extract and vitamin E on electrocardiographic, biochemical and apoptotic changes in isoproterenol induced myocardial infarction in rats. Pharmacologia. 2015;(5):178-185
[104] Farag NE, El-Kherbetawy MK,
Ismail HM, Abdelrady AM, Toraih EA, Abdelbasset WK, etal. Differential effect of three macrolide antibiotics on cardiac pathology and electrophysiology in a myocardial infarction rat model: Influence on sodium Nav1.5 channel expression. Pharmaceuticals. 2021;:597-603
[105] Taskin E, Kindap EK, Ozdogan K,
Aycan MBY, Dursun N. Acute adriamycin-induced cardiotoxicity is exacerbated by angiotension II. Cytotechnology. 2016;(1):33-43
[106] Da Silva VJD, Neto EF, Salgado HC,
Junior RF. Chronic converting enzyme inhibition normalizes QT interval in aging rats. Brazilian Journal of Medical and Biological Research. 2002;(9):1025-1031
[107] Walsh EP, Alexander ME, Cecchin F.
Chapter 12 - electrocardiography and introduction to electrophysiologic techniques. In: Nadas’ Pediatric

Cardiology. 2nd ed. Amsterdam: Elsevier Inc; 2006. pp. 145-181
[108] Surawicz B, Knilans TK. Normal
electrocardiogram. PR interval. In: Chou’s Electrocardiography in Clinical Practice. 6th ed. Amsterdam: Elsevier Inc; 2008
[109] Richig JW, Sleeper MM. PR
(PQ), QRS, QT, and other issues. In: Electrocardiography of Laboratory Animals. 2nd ed. London, UK: Academic Press, Elsevier Inc; 2019
[110] Mauer DE, Naegeli B, Straumann E,
Bertel O, Frielingsdorf J. Quality of life and exercise capacity in patients with prolonged PQ interval and dual chamber pacemakers: A randomized comparison of permanent ventricular stimulation vs intrinsic AV conduction. EP Europace. 2003;(4):411-417
[111] Portnov A. PQ interval extension.
Diseases of the heart and blood vessels (cardiology). PQ interval extension: symptoms, diagnosis, treatment (iliveok.com). 2021.
[112] Lown B, Ganong WF, Levine SA.
The syndrome of short P-R interval normal QRS complex and paroxysmal rapid heart action. Circulation. 1952;:693-706
[113] Zada M, Lo Q , Trivedi SJ,
Harapoz M, Boyd AC, Devine K, etal. Electrocardiographic characteristics and their correlation with echocardiographic alterations in fabry disease. Journal of Cardiovascular Development and Disease. 2022;(1):11
[114] Shumilova TE, Shereshkov VI,
Yanvareva IN, Nozdrachev AD. Peculiarities of myocardial electrogenesis in laboratory rats under conditions of acute nitrite intoxication. Journal of Evolutionary Biochemistry and Phys. 2010;(2):179-188
Rat Electrocardiography and General Anesthesia DOI: http://dx.doi.org/10.5772/.104928
[115]
64
https://t.me/medicina_free
Sadeghi N, Saadatfard S, Dianat M, Abedi H, Dehghani K. Combination effects of gallic acid and cyclosporine a during ischemia/ reperfusion on rat electrocardiogram parameters and arrhythmia. Physiology and Pharmacology. 2021;:162-170
[116]
Damasceno DD, Lima MP, Motta DF, Ferreira AJ, Quintão-Junior JF, Drummond-Junior LR, etal. Cardiovascular and eletrocardiographic parameters after tonin administration in Wistar rats. Regulatory Peptides. 2013;:30-36
[117]
Gohma H, Kuramoto T, Kuwamura M, Okajima R, Tanimoto N, Yamasaki K, etal. WTC deafness Kyoto (dfk): A rat model for extensive investigations of Kcnq1 functions. Physiological Genomics. 2006;:198-206
[118]
Mamalyga ML. Heart rate regulation at different levels of convulsive readiness. Bulletin of Experimental Biology and Medicine. 2013;(4):425-428
[119]
Adeyemi O, Parker N, Pointon A, Rolf M. A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. Journal of Pharmacological and Toxicological Methods. 2020;:106679
of WBN/Kob rats. Laboratory Animals. 1990;(3):288-291
[123] Van Buren T, Schiereck P, De
Ruiter GJW, Gispen WH, De Wildt DJ. Vagal efferent control of electrical properties of the heart in experimental diabetes. Acta Diabetologica. 1998;(1): 19-25
[124] Lee JK, Nishiyama A, Kambe F,
Seo H, Takeuchi S, Kamiya K, etal. Downregulation of voltage-gated K+ channels in rat heart with right ventricular hypertrophy. American Journal of Physiology. Heart and Circulatory Physiology. 1999;(5):H1725-H1731
[125] Barrett TD, Hayes ES, Yong SL,
Zolotoy AB, Abraham S, Walker MJA. Ischaemia selectivity confers efficacy for suppression of ischaemia-induced arrhythmias in rats. European Journal of Pharmacology. 2000;(3):365-374
[126] Ghelfi E, Ramos-Rhoden C,
Wellenius GA, Lawrence J, Gonzalez­Flecha B. Cardiac oxidative stress and electrophysiological changes in rats exposed to concentrated ambient particles are mediated by TRP-dependent pulmonary reflexes. Toxicological Sciences. 2008;(2):328-336
[120]
Hamdy DA, Brocks DR. Experimental hyperlipidemia causes an increase in the electrocardiographic changes associated with amiodarone. Journal of Cardiovascular Pharmacology. 2009;:1-8
[121]
Patel JP, Brocks DR. Effect of experimental hyperlipidaemia on the electrocardiographic effects of repeated doses of halofantrine in rats. British Journal of Pharmacology. 2010;(6):1427-1440
[122]
Machidal K, Dol K, Kaburaki M, Sugano S. Electrocardiographical findings

[127] Regan CP, Stump GL, Wallace AA,
Anderson KD, McIntyre CJ, Liverton NJ, etal. In vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-1, in rat, dog, and nonhuman primate. Journal of Cardiovascular Pharmacology. 2007;(4):236-245
[128] Medeiros DM, Shiry LJ,
McCune SA. Marginal copper intakes over a protracted period in genetically and nongenetically susceptible heart disease rats disturb electrocardiograms and enhance lipid deposition. Nutrition Research. 2005;(7):663-372
Novel Pathogenesis and Treatments for Cardiovascular Disease
65
https://t.me/medicina_free
[129] Medei E, Lima-Leopoldo AP,
Pereira-Junior PP, Leopoldo AS, Campos DHS, Raimundo JM, etal. Could a high-fat diet rich in unsaturated fatty acids impair the cardiovascular system? The Canadian Journal of Cardiology. 2010;(10):542-548
[130] Milliez P, Deangelis N,
Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E, etal. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. European Heart Journal. 2005;(20):2193-2199
[131] Haugan K, Lam HR, Knudsen CB,
Petersen JS. Atrial fibrillation in rats induced by rapid transesophageal atrial pacing during brief episodes of asphyxia: A new in vivo model. Journal of Cardiovascular Pharmacology. 2004;(1):125-135
[132] Nattel S, Shiroshita-Takeshita A,
Brundel BJ, Rivard L. Mechanisms of atrial fibrillation: Lessons from animal models. Progress in Cardiovascular Diseases. 2005;:9-28
prophylactic effects of metoprolol, diltiazem, and pilocarpine on hypoglycemia induced prolongation of QT interval. Cureus. 2021;(3):e14058
[137] Jain PG, Mahajan UB, Shinde SD,
Surana SJ. Cardioprotective role of FA against isoproterenol induced cardiac toxicity. Molecular Biology Reports. 2018;(5):1357-1365
[138] Sultan F, Kaur R, Mir AH,
Maqbool I, Lonare M, Singh D, etal. Rosuvastatin and retinoic acid may act as pleiotropic agents’ against β-adrenergic agonist-induced acute myocardial injury through modulation of multiple signalling pathways. Chemico-Biological Interactions. 2020;:108970
[139] Gogelein H, Ruetten H, Albus U,
Englert HC, Busch AE. Effects of the cardioselective K-ATP channel blocker HMR 1098 on cardiac function in isolated perfused working rat hearts and
reperfusion. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2001;(1): 33-41
[133] Gupta C, Omanwar S, Bubber P,
Saidullah B. ECG alterations precedes cardiac hypertrophy in rat model of diabetes. Open Access Journal of Toxicology. 2018;(5)
[134] Shamala S, Krishna KL.
Cardioprotective activity of fruit extracts of momordica dioca roxb on doxorubicin induced toxicity on rats. Science International. 2013;(12):392-400
[135] Badole SL, Jangam GB, Chaudhari SM,
Ghule AE, Zanwar AA. L-glutamine supplementation prevents the development of experimental diabetic cardiomyopathy in streptozotocin-nicotinamide induced diabetic rats. PLoS One. 2014;(3):e92697
[136] Cagiltay E, Pouwels S, Erbas O,
Taskiran D, Tas SK, Aslan I. The

[140] Di Filippo C, D'Amico M,
Marfella R, Berrino L, Giugliano D, Rossi F. Endothelin-1 receptor antagonists reduce cardiac electrical instability induced by high glucose in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. 2002;(3):193-197
[141] Panoulas VF, Toms TE,
Douglas KMJ, Sandoo A, Metsios GS, Stavropoulos-Kalinoglou A, etal. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: An association driven by high inflammatory burden. Rheumatology. 2014;(1):131-137
[142] Jayasinghe R, Kovoor P. Drugs and
the QTc interval. Australian Prescriber. 2002;:63-65
Rat Electrocardiography and General Anesthesia DOI: http://dx.doi.org/10.5772/.104928
[143]
66
https://t.me/medicina_free
Kmecova J, Klimas J. Heart rate correction of the QT duration in rats. European Journal of Pharmacology. 2010;(2-3):187-192
[144]
Rossing P, Breum L, Major­Pedersen A, Sato A, Winding H, Pietersen A, etal. Prolonged QTc interval predicts mortality in patients with type 1 diabetes mellitus. Diabetic Medicine. 2001;(3):199-205
a single whole-body exposure to sarin vapor in rats. Toxicological Sciences. 2005;:385-390
[151] Howden R, Hanlon PR, Petranka JG,
Kleeberger S, Bucher J, Dunnick J, etal. Ephedrine plus caffeine causes age­dependent cardiovascular responses in Fischer 344 rats. American Journal of Physiology Heart and Circulatory Physiology. 2005;:H2219-H2224
[145]
Andršová I, Hnatkova K, Šišáková M, Toman O, Smetana P, Huster KM, etal. Sex and rate change differences in QT/RR hysteresis in healthy subjects. Frontiers in Physiology. 2022;:2473
[146]
Van Noord C, Eijgelsjeim M, Stricker BHC. Drug- and non-drug­associated QT interval prolongation. British Journal of Clinical Pharmacology. 2010;(1):16-23
[147]
Hayes E, Pugsley MK, Penz WP, Adaikan G, Walker MJ. Relationship between QaT and RR intervals in rats, Guinea pigs, rabbits, and primates. Journal of Pharmacological and Toxicological Methods. 1994;:201-207
[148]
Tavakoli S, Hajrasouliha AR, Jabehdar-Maralani P, Ebrahimi F, Solhpour A, Sadeghipour H, etal. Reduced susceptibility to epinephrine-induced arrhythmias in cirrhotic rats: The roles of nitric oxide and endogenous opioid peptides. Journal of Hepatology. 2007;:432-439
[152] Lamb CM, Hazari MS, Haykal-
Coates N, Carll AP, Krantz QT, King C, etal. Divergent electrocardiographic responses to whole and particle-free diesel exhaust inhalation in spontaneously hypertensive rats. Toxicological Sciences. 2012;(2):558-568
[153] Nwokocha C, Palacios J,
Simirgiotis MJ, Thomas J, Nwokocha M, Young L, etal. Aqueous extract from leaf of Artocarpus altilis provides cardio-protection from isoproterenol induced myocardial damage in rats: Negative chronotropic and inotropic effects. Journal of Ethnopharmacology. 2017;:163-170
[154] Mohammed HS, Hosny EN,
Khadrawy YA, Magdy M, Attia YS, Sayed OA, etal. Protective effect of curcumin nanoparticles against cardiotoxicity induced by doxorubicin in rat. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1866;(5):165665
[149]
Volk T, Nguyen TH, Schultz JH, Faulhaber J, Ehmke H. Regional alterations of repolarizing K
+
ventricular free wall of rats with ascending aortic stenosis. The Journal of Physiology. 2001;:443-455
[150]
Allon N, Rabinovitz I, Manistersky E, Weissman BA, Grauer E. Acute and long-lasting cardiac changes following
currents among the left
Chapter 3
67
https://t.me/medicina_free
G Protein-Coupled Receptor Regulation in Cardiovascular Disease: Role of G Protein-Coupled Receptor Kinases
Asma S.Alonazi, Anfal F.Bin Dayel, Tahani K.Alshammari and Nouf M.Alrasheed
Abstract
G pr
otein-coupled receptor kinases (GRKs), the negative regulators of G protein­coupled receptors (GPCRs), have a key role in cardiovascular disease pathophysiology. Alteration in GRKs’ expressions and/or kinase activity has been reported in preclinical animal models as well as in patients with cardiovascular diseases. This alteration might be a contributing factor to disease progression by a variety of mechanisms such as non­canonical transduction pathways. The current chapter is aimed to expand our knowl­edge and understanding of the function of GRKs in cardiovascular diseases, highlight their involvement, and illustrate the possible mechanistic role of GRKs in hypertensive vascular diseases and cardiac myopathy. The current chapter also is endeavoured to identify the potential molecular mechanisms by which GRKs participate in cardiovas­cular disease progression. Building the basics knowledge about GRKs in cardiovascular diseases will help to assess the potential utilization of GRKs as therapeutic targets and to examine the possible approaches to modulate their protein expression or to inhibit their kinase activity to prevent or attenuate cardiovascular disease progression.
Keywords: GRK2, GRK5, GPCR regulation, cardiovascular diseases, heart failure, hypertension, myocardial infarction
. Introduction
Cardiovascular diseases consider as one of the major causes of death, contributing to approximately 30% of all deaths globally. In Kingdom of Saudi Arabia, approximately 37% deaths are caused by cardiovascular diseases [1]. Elevated cardiovascular disease­related morbidity and mortality result from a complex pathophysiological process including activation of many signaling transduction pathways, resulting in modifica­tion in cardiac/vascular structure, remodeling, and ultimately alteration in the func­tionality, which contributes to disease progression. Of importance, G protein-coupled receptors (GPCR) play a key fundamental role in various transductions signaling that participate in cardiovascular diseases pathophysiological progression. GPCRs are a
Novel Pathogenesis and Treatments for Cardiovascular Disease
68
https://t.me/medicina_free
superfamily of heptahelical integral membrane proteins, which respond to various stimuli. They are responsible for transduction of a plethora of signaling networks that involve in physiological and pathological actions in cardiovascular system [2, 3]. The activation of α-adrenergic, β-adrenergic, muscarinic, angiotensin II type 1 receptor (AT1) and endothelin (ETA) receptors are involved in cardiac contractility, vascular resistance, vascular and cardiac remodeling. In addition, the effect of neurohumoral systems on cardiac contractility and blood vessel tone mainly transmit their signals via corresponding GPCR. These types of receptors and their downstream transduction systems are targets of various drugs used in the treatment of cardiovascular diseases [4].
In case of hypertension, GPCRs play fundamental function in blood vessel diam­eter, which is mainly controlled by either contraction or relaxation of vascular smooth muscle cells. During contraction, GPCR mediated phosphorylation of contractile proteins [5]. Vasoactive peptides such as noradrenaline, angiotensin II, endothelin 1, and vasopressin activated their corresponding G
coupled GPCR, results in stimula-
αq
tion of phospholipase C-β, resulting in the formation of inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to their corresponding receptors which is inositol trisphosphate receptors (IP3Rs) in the sarcoplasmic reticulum; the intracel­lular Ca2+ store. Activation of IP3Rs resulting in efflux of Ca2+ into the cytoplasm. On other hand, DAG activates protein kinase C (PKC), promoting Ca2+ influx via enhancing the vascular channels activity such as voltage-dependent L-type Ca2+ channels. Elevated intracellular Ca2+ concentration [Ca2+]i binds to calmodulin, creating Ca2+-calmodulin complex which activate MLC kinase (MLCK) followed by phosphorylation of contractile proteins that promote myosin-actin filament interac­tions and consequently smooth muscle contraction [6–11]. Contraction of vascular smooth muscle cells could persist via regulation of MLC phosphatase (MLCP). Vasoactive peptides also regulate the dephosphorylation of MLC phosphatase via dif­ferent mechanisms. They utilize the PLC-DAG-PKC pathway, which in turn inhibits phosphatase activity and thus stimulates persistent contraction [12]. In addition, they activate RhoA-Rho kinase pathway, which phosphorylates MLCP and inhibits its activity [13, 14]. On the other hand, a low [Ca2+]i concentration and increased activity of MLC phosphatase promoting vascular smooth muscle cell relaxation [15]. Gαs-coupled GPCR mediated blood vessel relaxation. Adrenaline, as vasodilator, acts on corresponding receptors, recruiting Gαs to stimulate adenylyl cyclase (AC), leading to the formation of cAMP and then activation of protein kinase A (PKA). PKA plays important role in decreasing [Ca2+]i concentrations via phosphorylation of MLCK. This results in activation of calcium pumps in the plasma membrane and sarcoplas­mic reticulum. Furthermore, promotes cell hyperpolarization by opening K+ channels promoting relaxation of vascular smooth muscle cells [8, 16, 17].
In case of heart failure, GPCR such as β-adrenergic receptors plays an essential role in cardiac function and in cardiac myocytes contractility. β1-adrenergic recep­tors couple to Gαs that activates adenylate cyclase (AC) and enhances cAMP mediate protein kinase A (PKA) activation which regulates different intracellular, sarco­lemma, and myofibrillar substrates, mediating positive inotropic and chronotropic effects [18]. G
subunits also activate downstream effectors that participate in
βγ
cardiac transduction pathways. Moreover, it has been reported that overexpression of β1-adrenergic receptors triggers early myocytes hypertrophy and interstitial fibrosis followed by marked cardiac dysfunction in mice [18]. In addition, β1-adrenergic receptors activate various downstream signaling participating in cardiac pathophysi­ological processes such as cardiac hypertrophy, which might progress to heart failure development [19–21]. β2-adrenergic receptors can couple to a dual G
αs/Gαi
subunits, it
G Protein-Coupled Receptor Regulation in Cardiovascular Disease: Role of G Protein-Coupled… DOI: http://dx.doi.org/10.5772/.105403
has been implicated in differential β2-adrenergic receptors mediated signaling such as
69
https://t.me/medicina_free
in myocyte apoptosis [22]. Therefore, β-adrenoceptor blockers are one of the standard pharmacotherapeutics agents used in the treatment of heart failure patients [23]. β-blockers also have been shown to reduce disease progression, mortality, and mor­bidity in patients with heart failure with reduced ejection fraction (HFrEF) [24]. This effect appears primarily related to the ability of β-adrenoceptor blockers to protect the heart from the harmful effects of receptor over-stimulation [25].
As the effect of neurohumoral systems on cardiovascular system mainly transmits
their signals via GPCRs, understanding of the GPCR regulation and their G-protein dependent/independent signaling reveals a novel therapeutic approach that could attenuate cardiovascular-related complications. In current chapter, we provide insight into the potential effect of GPCR negative regulators, focusing particularly on G protein-coupled receptor kinases (GRKs) and their possible effect on cardiovascular diseases.
. GPCRs regulations
Repeated or prolonged/continues agonist stimulation of GPCRs resulted in loss
of receptor response characterized as receptor desensitization. It can be described as physical uncoupling of G proteins from their associate receptors subsequent in diminish their ability to initiate intracellular signaling cascades [26]. As shown in Figure , receptor desensitization process is initiated by receptor phosphorylation. It can be mediated by G protein-coupled receptor kinases (GRKs), which phosphorylate agonist-bound active receptor inducing homologous type of receptor desensitization [27]. Receptor phosphorylation can be also mediated by second messenger kinases such as PKA and PKC, which can phosphorylate receptors regardless of whether the GPCR is occupied by agonist or not, thus producing heterologous type of receptor desensitization [27–29]. Receptor phosphorylation subsequently increases the affinity of the receptors for β-arrestins proteins binding, consequently prevents further recep­tors-G protein interactions and therefore termination of G protein-related signaling
Figure 1. GPCR desensitization and related signaling transductions pathways. GPCR desensitization by GRKs and β-arrestins process initiated with ligand binding, receptor activation and dissociation of G protein. Consequently, GRKs phosphorylate agonist-occupied GPCRs (activated receptors) at third intracellular loop or C-terminal. Receptor phosphorylation resulting in enhances the affinity for β-arrestin recruitment then binding to the receptors causing termination of G-protein dependent transduction signaling and receptor desensitization. After that, the receptors undergo internalization and initiation of G protein-independent transduction signaling.
Novel Pathogenesis and Treatments for Cardiovascular Disease
70
https://t.me/medicina_free
[30]. Accordingly, the phosphorylated GPCR/β-arrestin complex is subjected for clathrin-mediated endocytosis, followed by either recycling, or degradation [31–33]. Importantly, β-arrestins function as ligand-regulated adaptor scaffolds that enable the transduction of signaling pathways in non-canonical manner [34].
. G protein-coupled receptors kinases (GRKs)
G Protein-Coupled Receptors Kinases (GRKs) are family of seven members of serine/threonine kinases [35]. They are allocated into three subcategories: the first category is visual GRKs including GRK1 and GRK7; the second and third categories are non-visual GRKs including β-adrenergic receptor kinase subcategory, containing GRK2 (β-ARK1) and GRK3 (β-ARK2) and; the GRK4 subcategory, containing GRK4, GRK5, and GRK6 [27]. Regarding GRKs tissue distribution, GRK1 and GRK7 are primarily expressed in the retina mediating photoreceptor regulation. GRK2, GRK3, GRK5, and GRK6 are ubiquitously expressed in various tissues; however, GRK4 is limitedly distributed to testes, kidneys, and some areas of the brain. Hence, GRK2, GRK3, GRK5, or GRK6 is the potential regulator for the majority of GPCRs [36–38].
In cardiovascular system, the distribution pattern and expression levels of GRK are crucial factors contributing to their functionality in various cell types. Previous reports show that GRK2, GRK3, and GRK5 are highly expressed in the human heart [39]. GRK isoforms distribution is different among various heart cells. GRK2 and GRK5 are expressed in almost all cardiac cells, while GRK3 distribution is limited to cardiac myocytes [4, 40]. GRK2 is expressed in the vascular endothelium, arte­rial smooth muscle, and in the myocardium. GRK2 is also expressed in the kidney, especially in the renal proximal tubule [41].
The structure of GRKs comprises of three domains: N-terminal; an amino terminal domain, central serine/threonine protein kinase/catalytic domain, and C-terminal; a carboxyl terminal domain. The N-terminal domain is implicated in receptor recognition. It includes a region of a regulator of G protein signaling (RGS) homology domain (RH) [31, 35]. In GRK2, Gβγ binding site has been mapped in the N-terminal region causing binding of GRK2 to cell membrane [42]. The central domain is a serine/threonine protein that exerts the kinase catalytic function in all GRKs. The C-terminal domain structure is different among GRKs subfamilies. It is implicated in GRK membrane localization. For instant, GRK5 is located at cell membrane level as the C-terminus of GRK5 contains lipid-binding sites that interact with the phospholipid in the cell membrane. On other hand, GRK2 and GRK3 are cytoplasmic proteins that are recruited to the plasma membrane upon agonist bind­ing and receptor activation. Their C-terminal domains contain pleckstrin homology (PH) domain, which comprises binding sites for the cell membrane phospholipid (PIP2) and Gβγ subunits [26, 35, 43]. As a multi-domain protein, GRK acts as a negative GPCR signaling regulator, terminating G protein-dependent signaling and initiating other G protein-independent signaling pathways [30, 44]. For instance, reported evidence reported that GRK functions are expanded more than receptors phosphorylation. GRKs are able to interact with various cellular proteins mediating non-canonical GPCR signaling [31, 45]. Of importance, GRK expression and activity are changed in many cardiovascular diseases such as in case of hypertension or heart failure. Thus, better understanding of the diseases associated with alteration in GRKs’ expression as well as their functional roles in cardiovascular system is fundamental to develop a new therapeutic target.